Article
Oncology
Peter Ruf, Hartwig W. Bauer, Alexandra Schoberth, Claudia Kellermann, Horst Lindhofer
Summary: Intravesical administration of catumaxomab in patients with EpCAM-positive recurrent non-muscle invasive bladder cancer has shown to be effective in eliminating tumor cells and increasing recurrence-free intervals without causing significant toxicity. Further clinical development of catumaxomab in this indication is warranted.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Saadiya Zia, Komal Tehreem, Sidra Batool, Mehreen Ishfaq, Shaher Bano Mirza, Shahrukh Khan, Majed N. Almashjary, Mohannad S. Hazzazi, Husam Qanash, Ahmad Shaikh, Roua S. Baty, Ibrahim Jafri, Nouf H. Alsubhi, Ghadeer I. Alrefaei, Rokayya Sami, Ramla Shahid
Summary: This study found that the expression of EpCAM in cancer cells was inhibited by costunolide, suggesting that costunolide could be a potential therapeutic biomolecule for leukemia.
Article
Multidisciplinary Sciences
Fatma E. Omar, Taylor P. Brown, William A. Gillanders, Timothy M. Fleming, Michael V. Smith, Ross Bremner, Narendra Sankpal
Summary: Next generation sequencing has identified novel therapeutic targets in human cancer mutations. Activating Ras oncogene mutations play a central role in oncogenesis, promoting the transformation of normal cells into tumor cells. This study investigated the role of altered localization of epithelial cell adhesion molecule (EpCAM) in Ras-expressing cells, revealing that EpCAM mutations can cooperate with H-Ras and promote epithelial-to-mesenchymal transition (EMT).
Review
Biochemistry & Molecular Biology
Taylor C. Brown, Narendra Sankpal, William E. Gillanders
Summary: Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that plays a crucial role in epithelial tissue homeostasis and is a target of molecular therapies for tumor biology. Its expression is frequently high in epithelial cancers and silenced in mesenchymal cancers. EpCAM's functional impact on tumor biology is multifunctional and depends on the predominant oncogenic signaling pathways in different cancer types. Its regulation during epithelial-to-mesenchymal transition (EMT) involves downregulation by extracellular signal-regulated kinases (ERK) and EMT transcription factors, as well as regulated intramembrane proteolysis (RIP).
Review
Oncology
Catherine R. Lewis, Neda Dadgar, Samuel A. Yellin, Vera S. Donnenberg, Albert D. Donnenberg, David L. Bartlett, Casey J. Allen, Patrick L. Wagner
Summary: This review explores the unique characteristics of gastric/gastroesophageal junction cancer (GC-PC) and peritoneal immune biology, and discusses potential immunotherapy strategies. By altering the peritoneal immune environment, regional cellular therapy could be more effective in treating GC-PC.
Article
Oncology
Angela Bella, Ignacio Melero, Pedro Berraondo, Fernando Aranda
Summary: Recent research has revealed the potential of locoregional immunotherapy, where cytokine-armored viral vectors can effectively target the omentum and induce a strong tumor-specific immune response while minimizing toxicity.
Article
Medicine, General & Internal
Claire Y. Li, Timothy Kennedy, Henry Richard Alexander
Summary: Malignant peritoneal mesothelioma is a rare malignancy that is diagnosed through cross sectional imaging and tissue biopsy. Surgical cytoreduction and chemotherapy are the preferred treatments, providing prolonged benefits to many patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Cecile Gaston, Simon De Beco, Bryant Doss, Meng Pan, Estelle Gauquelin, Joseph D'Alessandro, Chwee Teck Lim, Benoit Ladoux, Delphine Delacour
Summary: The study highlights the importance of EpCAM/RhoA co-trafficking and actomyosin rearrangement in cell spreading and polarization, furthering our understanding of how biochemical and mechanical properties contribute to cell plasticity.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, Research & Experimental
Chi-Chiu Lee, Chia-Jui Yu, Sushree Shankar Panda, Kai-Chi Chen, Kang-Hao Liang, Wan-Chen Huang, Yu-Shiuan Wang, Pei-Chin Ho, Han-Chung Wu
Summary: This study explores the interaction between EpCAM and HGFR and its impact on the metastatic and invasive abilities of colon cancer cells. The results demonstrate that EpCAM binds to HGFR and activates the ERK and FAK-AKT signaling pathways, leading to the promotion of colon cancer metastasis. Furthermore, the combined treatment with EpCAM and HGFR antibodies significantly inhibits tumor progression and improves patient survival.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Julia Kleber, Jordi Yang Zhou, Florian Weber, Florian Bitterer, Patricia Hauer, Paul Kupke, Katharina Kronenberg, Edward K. Geissler, Hans J. Schlitt, Matthias Hornung, James A. Hutchinson, Jens M. Werner
Summary: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal carcinomatosis (PC) from colorectal cancer (CRC). However, survival outcomes are only marginally superior to other treatments. This study investigates the immune phenotype of T cells in patients with PC.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Yang Gao, Wan-Hung Fan, Zhengbo Song, Haizhou Lou, Xixong Kang
Summary: By comparing the CTC detection rates with EpCAM and CSV antibodies in different solid tumors, it was found that EpCAM has higher detection rates in colorectal cancer, while CSV performs better in sarcoma.
Article
Oncology
Angela Bella, Leire Arrizabalaga, Claudia Augusta Di Trani, Assunta Cirella, Myriam Fernandez-Sendin, Celia Gomar, Joan Salvador Russo-Cabrera, Inmaculada Rodriguez, Jose Gonzalez-Gomariz, Maite Alvarez, Alvaro Teijeira, Jose Medina-Echeverz, Maria Hinterberger, Hubertus Hochrein, Ignacio Melero, Pedro Berraondo, Fernando Aranda
Summary: This study evaluated different recombinant-modified vaccinia virus Ankara (rMVA) vectors in preclinical peritoneal carcinomatosis models and found that the vector encoding both CD40L and CD137L can enhance immune response and improve survival in mice with peritoneal carcinomatosis.
Review
Oncology
Mefotse Saha Cyrelle Ornella, Narayanasamy Badrinath, Kyeong-Ae Kim, Jung Hee Kim, Euna Cho, Tae-Ho Hwang, Jae-Joon Kim
Summary: Peritoneal carcinomatosis is a challenging condition that has limited treatment options. However, recent advances in immunotherapy, such as immune checkpoint inhibitors and CAR-T cells, show promise in improving outcomes for patients. Combining different immunotherapeutic approaches may further enhance treatment efficacy. Further research is needed, but immunotherapy holds potential as an effective and tolerable treatment for peritoneal carcinomatosis.
Article
Biochemistry & Molecular Biology
Reyhaneh Roshan, Shamsi Naderi, Mahdi Behdani, Reza Ahangari Cohan, Fatemeh Kazemi-Lomedasht
Summary: In this study, an anti-EpCAM immunotoxin was developed and shown to have anti-proliferative and apoptotic activity in MCF-7 cells, as well as the ability to significantly reduce tumor size in vivo, indicating its potential as a novel therapeutic for cancer therapy.
MOLECULAR BIOTECHNOLOGY
(2023)
Article
Oncology
Valentina Palacio-Castaneda, Bas van de Crommert, Elke Verploegen, Mike Overeem, Jenny van Oostrum, Wouter P. R. Verdurmen
Summary: Researchers have developed modular engineered proteins that can selectively degrade Ras in tumor cells that overexpress EpCAM, using endopeptidases fused with either Pseudomonas aeruginosa exotoxin A or diphtheria toxin. These proteins showed effective Ras degradation and selective toxicity towards tumor cells in both 2D and 3D tumor models, while non-cancerous fibroblasts remained unaffected.
MOLECULAR THERAPY-ONCOLYTICS
(2023)